Difference between revisions of "Asparaginase (Elspar)"
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase<ref name="insert">[http://www.lundbeck.com/upload/us/files/pdf/Products/Elspar_PI_US_EN.pdf Asparaginase (Elspar) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/asparaginase.pdf Asparaginase (Elspar) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.<ref name="insert">[http://www.lundbeck.com/upload/us/files/pdf/Products/Elspar_PI_US_EN.pdf Asparaginase (Elspar) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/asparaginase.pdf Asparaginase (Elspar) package insert (locally hosted backup)]</ref> |
<br>Route: IV/IM | <br>Route: IV/IM | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== |
Revision as of 15:50, 29 November 2011
General information
Class/mechanism: Depletes plasma asparagine, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2]
Route: IV/IM
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)